<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138420</url>
  </required_header>
  <id_info>
    <org_study_id>PT1124/14</org_study_id>
    <nct_id>NCT04138420</nct_id>
  </id_info>
  <brief_title>Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab</brief_title>
  <official_title>Study of Retinal and Vascular Features by Optical Coherence Tomography and Optical Coherence Tomography Angiography After Intravitreal Injections of Bevacizumab in Exudative Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the retinal and vascular features in patients with macular degeneration
      under the effects of Bevacizumab intravitreal injections using optical coherence tomography
      and optical coherence tomography angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bevacizumab is a vascular endothelial growth factor antagonist represent an efficacy
      treatment for exudative age-related macular degeneration acting on vascular
      hyperpermeability.

      The optical coherence tomography and optical coherence tomography angiography represent novel
      and non-invasive diagnostic techniques that allow a detailed and quantitative analysis of
      retinal and vascular features.

      The study evaluates the changes in optical coherence tomography and optical coherence
      tomography angiography parameters at baseline and after three monthly injections of
      Bevacizumab in exudative AMD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2017</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 25, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of retinal structural features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab</measure>
    <time_frame>three months</time_frame>
    <description>The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography. The parameters analyzed by optical coherence tomography: Central Macular Thickness and Subfoveal Choroidal thickness (microns).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study of retinal vascular features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab</measure>
    <time_frame>three months</time_frame>
    <description>The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillaris vessel density (%).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Patients receiving Bevacizumab</arm_group_label>
    <description>Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab Injection</intervention_name>
    <description>Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)</description>
    <arm_group_label>Patients receiving Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participans were older than 50 years with diagnosis of exudative age-relative macular
        degeneration. They did not present other ophthalmological disease and did not receive
        previous treatment before Bevacizumab.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age older than 50 years, diagnosis of exudative age-related macular degeneration,
             treatment-na√Øve with Bevacizumab for exudative age-related macular degeneration.

        Exclusion Criteria:

          -  age younger than 50 years, diagnosis of exudative macular degeneration due to other
             causes, previous treatments before Bevacizumab for exudative age-related macular
             degeneration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilda Cennamo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Naples &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gilda Cennamo</investigator_full_name>
    <investigator_title>Gilda Cennamo</investigator_title>
  </responsible_party>
  <keyword>optical coherence tomography angiography</keyword>
  <keyword>optical coherence tomography angiography angiography</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>vascular endothelial growth factor antagonists</keyword>
  <keyword>intravitreal injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

